Ifinatamab Deruxtecan not checked

Daiichi Sankyo · DS-7300a · MK-2400

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1/2 trial completes
Trials
13 active
13 in total · 11 in the EU
Targets
 

What this is

How it works
An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
How it’s given
“Administered via intravenous (IV) infusion every 3 weeks (q3w) until disease progression, unacceptable adverse events (AEs), or other cessation of treatment”In the company’s words, NCT06925737 on ClinicalTrials.gov
Tested for
Small Cell Lung Cancer (2 trials), Carcinoma, Non-Small-Cell Lung (2 trials), Esophageal Squamous Cell Carcinoma, Prostate Cancer, Prostatic Neoplasms, Extensive-stage Small-cell Lung Cancer, Advanced Solid Tumor, Malignant Solid Tumor and 7 more
Main trialPhase 3
“This study is designed to compare the efficacy and safety of I-DXd with treatment of physician's choice in participants with relapsed small cell lung cancer (SCLC).”In the company’s words, NCT06203210 on ClinicalTrials.gov
Other names
DS-7300a · MK-2400 · I-DXd

Other drugs for Small Cell Lung Cancer

All 118 drugs for Small Cell Lung Cancer

Coming up12

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials13

TrialPhaseCompletesWhat it tests
Phase 3Recruiting 30 Jan 2028 A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
Phase 3Recruiting 1 Jun 2028 A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
Phase 3Recruiting 26 Jun 2028 A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
Phase 2Active, not recruiting 3 Mar 2025 Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Phase 2Active, not recruiting 12 Mar 2032 A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)
Phase 1/2Active, not recruiting 30 Apr 2027 Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors
Phase 1/2Recruiting 20 Jul 2027 A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)
Phase 1/2Active, not recruiting 28 Jan 2028 A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)
Phase 1/2Recruiting 25 Jul 2028 A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Phase 1/2Recruiting 15 Feb 2029 A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)
Phase 1/2Recruiting 17 Aug 2031 A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)
Phase 1/2Recruiting 1 Oct 2031 A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
Phase 1/2Recruiting 13 Feb 2032 KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Ifinatamab Deruxtecan

Following is part of Solo: you see every change to Ifinatamab Deruxtecan the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in